Experimental design: Adult patients with advanced MM were entered on a multicenter phase II study.

These preliminary results show the feasibility of this approach in advanced MM patients with heavily infiltrated marrow.

These agents have been incorporated into numerous treatment schedules for newly diagnosed as well as more advanced MM patients.